Gustavo Viani: How has the treatment landscape for CNS primary lymphoma evolved over decades?
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a recent article by Kathryn R Tringale on X:
“How has the treatment landscape for CNS primary lymphoma evolved over decades?
This study dives deep into consolidation strategies like RD-WBRT, AHCT, and NMC, unraveling the balance between efficacy and safety.
Discover why RD-WBRT might still be a game-changer for those ineligible for AHCT.
Objective: Evaluate evolving patterns and outcomes of consolidation strategies (1983-2020) MSKCC.
Methods: Analyzed 559 by consolidation type (e.g., RD-WBRT, AHCT, NMC). RD-WBRT = Reduced-Dose Whole-Brain (≤24 Gy), designed to balance disease control and reduce neurotoxicity.
Findings:
- RD-WBRT PFS but use declined (61% →12%).
- AHCT use increased.
- NMC increasingly used despite suboptimal outcomes.
RD-WBRT remains a viable option for AHCT-ineligible.”
Authors: Kathryn R Tringale, Michael Scordo, Joachim Yahalom, Charlie White, Zhigang Zhang, Javin Schefflein, Gustav Cederquist, Lauren R Schaff, Lisa DeAngelis, Brandon S Imber and Christian Grommes
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
More posts featuring Gustavo Viani.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023